Fierce Pharma April 30, 2024
Biopharma companies and industry lobbying groups are striking out in their legal efforts to challenge price-cutting measures in the Inflation Reduction Act.
On Monday, a New Jersey federal judge tossed (PDF) lawsuits by Bristol Myers Squibb and Johnson & Johnson, which questioned the constitutionality of the U.S. government requiring drugmakers to negotiate with Medicare on the pricing of their products.
The dismissal comes two months after a Delaware federal court rejected a similar lawsuit by AstraZeneca. On Monday, the European drugmaker filed its challenge of the decision with the U.S. Court of Appeals. Similarly, J&J said it will appeal Monday’s decision.
“This is a disappointing ruling for patients and America’s leadership role in medical innovation,” a J&J spokesperson wrote in...
Today's Sponsors
Today's Sponsor